SCHEMBL1574973

SCHEMBL1574973

CSc1cccc(NC(=O)N2CC(N3CCc4ccccc43)C2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.58
NPC1 O15118 5/20 0.50
RAB9A P51151 5/20 0.50
POLB P06746 2/20 0.50
GAA P10253 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
TP53 P04637 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 2/20 0.44
UBE2M P61081 1/20 0.44
DCUN1D1 Q96GG9 1/20 0.44
PKM P14618 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575363 0.94 MAPT (0.56) MAPTNPC1RAB9APOLBGAA
SCHEMBL1574958 0.86 ALDH1A1 (0.55) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL1575181 0.84 NPC1 (0.60) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1575472 0.84 NPC1 (0.63) MAPTNPC1RAB9AGAAMEN1
SCHEMBL1575344 0.84 NPC1 (0.54) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL1575034 0.82 RAB9A (0.52) NPC1RAB9APOLBMEN1KMT2A
SCHEMBL1574937 0.82 NPC1 (0.66) MAPTNPC1RAB9APOLBGAA
SCHEMBL1575520 0.81 NPC1 (0.61) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL1574352 0.81 NPC1 (0.51) NPC1RAB9APOLBTP53SMN1; SMN2
SCHEMBL1574545 0.81 GRIN2B (0.56) MAPTRAB9AGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB MAPT 3908/4885NPC1 413/4885RAB9A 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.